Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
Phase 2
Completed
- Conditions
- Myelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00067028
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Randomized Double Cord Blood Transplant Study
Phase 2
Completed
- Conditions
- Leukemia, Lymphocytic, AcuteLeukemia, Myelocytic, AcuteLeukemia, Myeloid, ChronicLymphoma, Non-Hodgkin
- Interventions
- Procedure: Expanded allogeneic cord blood (CB)Procedure: One Unmanipulated and One Expanded Cord Blood UnitRadiation: Total body irradiation (TBI)
- First Posted Date
- 2003-08-11
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT00067002
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
Phase 2
Completed
- Conditions
- Esophageal CancerGastric Cancer
- Interventions
- First Posted Date
- 2003-07-25
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00006081
- Locations
- 🇺🇸
CCOP - M.D. Anderson Research Base, Houston, Texas, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- Leukemia, MyeloidMyelodysplastic Syndromes
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00065143
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
- First Posted Date
- 2003-07-15
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00003645
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Biological: Recombinant Interferon Alfa (INF alpha)
- First Posted Date
- 2003-07-11
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00002965
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00063258
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
- First Posted Date
- 2003-06-20
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00063076
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Hepatic Artery Infusion of CD34+ Cells
Phase 1
Withdrawn
- Conditions
- Stem Cell TransplantationLiver Diseases
- Interventions
- Procedure: Hepatic artery infusion of CD34+ cellsDevice: Cobe Spectra
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00062543
Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
Phase 2
Terminated
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00062023
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath